VIDEO: Linzagolix is a ‘win-win’ for patients with uterine fibroids

SAN DIEGO — Several abstracts were presented at the ACOG Annual Clinical & Scientific Meeting on the efficacy and safety of linzagolix, an investigational oral GnRH antagonist being developed for the treatment of fibroid-related symptoms.

In this video, Linda Bradley, MD, a professor of OB/GYN and reproductive biology at the Cleveland Clinic and the medical director of the American Association of Gynecologic Laparoscopists, discusses the results from the randomized, double-blind, placebo-controlled phase 3 trials PRIMROSE 1 and PRIMROSE 2.

“I think this is going to be a win-win for our patients, to be able to offer them new doses with and without add-back therapy, and these patients can have improvement in their quality of life with safety, efficacy and a well-designed clinical trial to show that this is a new drug — investigational right now — that we hope will be able to be approved,” Bradley said.

References:

• Al-Hendy A, et al. Abstract 104. Presented at: ACOG Annual Clinical & Scientific Meeting; May 6-8, 2022; San Diego.
• Al-Hendy A, et al. Abstract 107. Presented at: ACOG Annual Clinical & Scientific Meeting; May 6-8, 2022; San Diego.
• Marsh EE, et al. Abstract 106. Presented at: ACOG Annual Clinical & Scientific Meeting; May 6-8, 2022; San Diego.
• Stewart EA, et al. Abstract 105. Presented at: ACOG Annual Clinical & Scientific Meeting; May 6-8, 2022; San Diego.
• Taylor HS, et al. Abstract 108. Presented at: ACOG Annual Clinical & Scientific Meeting; May 6-8, 2022; San Diego.